IFN-b is the first disease-modifying therapy to treat MS, which increases the concentration of anti-inflammatory agents and downregulates the expression of proinflammatory cytokines to reduce migration of inflammatory cells across the BBB [20]. Here, IFNB1 is linked to myeloid sarcoma.